Identification

Name
Prochlorperazine
Accession Number
DB00433  (APRD00624)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Structure
Thumb
Synonyms
  • 2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine
  • 2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
  • 3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
  • 3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
  • Capazine
  • Chlormeprazine
  • Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
  • Chloropernazine
  • Emetiral
  • N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine
  • Prochlorperazin
  • Prochlorpérazine
  • Prochlorperazinum
  • Prochlorpermazine
  • Prochlorpromazine
  • Procloperazine
  • Proclorperazina
External IDs
Bayer A 173 / RP 6140 / SKF 4657
Product Ingredients
IngredientUNIICASInChI Key
Prochlorperazine dimaleateNot AvailableNot AvailableNot applicable
Prochlorperazine edisylatePG20W5VQZS1257-78-9SWOUGRBFXFILIB-UHFFFAOYSA-N
Prochlorperazine maleateI1T8O1JTL684-02-6DSKIOWHQLUWFLG-SPIKMXEPSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS Prochlorperazine Inj 5mg/mlSolution5 mgIntramuscular; IntravenousPharmascience Inc1989-12-31Not applicableCanada
ProchlorazineTablet10 mgOralAa Pharma Inc2000-02-09Not applicableCanada
ProchlorazineTablet5 mgOralAa Pharma Inc2000-02-09Not applicableCanada
Prochlorperazine Mesylate Inj 5mg/mlLiquid5 mgIntramuscular; IntravenousSandoz Canada Incorporated1989-12-31Not applicableCanada
Sandoz ProchlorperazineSuppository10 mgRectalSandoz Canada Incorporated1989-12-31Not applicableCanada
StemetilSuppository10 mgRectalSanofi Aventis1958-12-312006-07-28Canada
StemetilSolution5 mgIntramuscular; IntravenousSanofi Aventis1957-12-312007-01-30Canada
Stemetil Liq 5mg/5mlSyrup5 mgOralAventis Pharma Ltd.1958-12-312005-08-01Canada
Stemetil Tab 10mgTablet10 mgOralAventis Pharma Ltd.1957-12-312005-08-01Canada
Stemetil Tab 5mgTablet5 mgOralAventis Pharma Ltd.1957-12-312005-08-01Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CompazineTablet, film coated10 mg/1OralPbm Pharmaceuticals Inc.2014-04-012016-01-31Us
CompazineTablet, film coated5 mg/1OralPbm Pharmaceuticals Inc.2014-04-012016-01-27Us
CompazineSuppository25 mg/1RectalPbm Pharmaceuticals Inc.2013-07-01Not applicableUs
ComproSuppository25 mg/1RectalPaddock Laboratories, Inc.2000-09-01Not applicableUs
ComproSuppository25 mg/1RectalPd Rx Pharmaceuticals, Inc.2000-09-01Not applicableUs
ComproSuppository25 mg/1RectalA S Medication Solutions2000-09-012017-06-20Us
Nu-prochlor Tab 10mgTablet10 mgOralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prochlor Tab 5mgTablet5 mgOralNu Pharm Inc1992-12-312012-09-04Canada
PMS-prochlorperazine Suppositoires 10mgSuppository10 mgRectalPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 10mgTablet10 mgOralPharmascience Inc1989-12-31Not applicableCanada
International/Other Brands
Buccastem (Reckitt Benckiser) / Emetiral (Zentiva) / Stemzine (Sanofi-Aventis) / Volimin (Chin Teng)
Categories
UNII
YHP6YLT61T
CAS number
58-38-8
Weight
Average: 373.943
Monoisotopic: 373.13794618
Chemical Formula
C20H24ClN3S
InChI Key
WIKYUJGCLQQFNW-UHFFFAOYSA-N
InChI
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1

Pharmacology

Indication

For the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.

Associated Conditions
Pharmacodynamics

Prochlorperazine is a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine. It shares many of the actions and adverse effects of the antipsychotics.

Mechanism of action

The mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension.

TargetActionsOrganism
AD(2) dopamine receptor
antagonist
Human
Absorption

Rapidly absorbed following oral administration

Volume of distribution
Not Available
Protein binding

91-99%

Metabolism

Hepatic. Undergoes metabolism in the gastric mucosa and on first pass through the liver, CYP2D6 and/or CYP3A4.

Route of elimination
Not Available
Half life

6 to 8 hours

Clearance
Not Available
Toxicity

Symptoms of central nervous system depression to the point of somnolence or coma. Agitation and restlessness may also occur. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever and autonomic reactions such as hypotension, dry mouth and ileus; LD50=400mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineProchlorperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineProchlorperazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Prochlorperazine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineProchlorperazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acetylglycinamide chloral hydrate.Experimental
AdinazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Allopregnanolone.Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.Approved, Investigational
AloglutamolAloglutamol can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlosetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Prochlorperazine.Approved, Withdrawn
AluminiumAluminium can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AlverineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amineptine.Illicit, Withdrawn
AmiodaroneThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideProchlorperazine may increase the antipsychotic activities of Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Prochlorperazine.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Prochlorperazine.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prochlorperazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amperozide.Experimental
AmphetamineProchlorperazine may decrease the stimulatory activities of Amphetamine.Approved, Illicit, Investigational
AmprenavirThe metabolism of Prochlorperazine can be decreased when combined with Amprenavir.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aniracetam.Experimental
AnisodamineThe serum concentration of Anisodamine can be increased when it is combined with Prochlorperazine.Investigational
ApalutamideThe serum concentration of Prochlorperazine can be decreased when it is combined with Apalutamide.Approved, Investigational
APD791The risk or severity of adverse effects can be increased when Prochlorperazine is combined with APD791.Investigational
ApomorphineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Apramycin.Experimental, Vet Approved
AprepitantThe serum concentration of Prochlorperazine can be increased when it is combined with Aprepitant.Approved, Investigational
AprobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole lauroxil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Prochlorperazine.Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Artemether is combined with Prochlorperazine.Approved
ArtemisininThe risk or severity of QTc prolongation can be increased when Artemisinin is combined with Prochlorperazine.Investigational
ArtemotilThe risk or severity of QTc prolongation can be increased when Artemotil is combined with Prochlorperazine.Approved
ArtenimolThe risk or severity of QTc prolongation can be increased when Artenimol is combined with Prochlorperazine.Approved, Investigational
ArtesunateThe risk or severity of QTc prolongation can be increased when Artesunate is combined with Prochlorperazine.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Asenapine.Approved
AtazanavirThe metabolism of Prochlorperazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Prochlorperazine.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Atomoxetine.Approved
AtovaquoneThe risk or severity of QTc prolongation can be increased when Atovaquone is combined with Prochlorperazine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Azaperone.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when Prochlorperazine is combined with AZD-3043.Investigational
AzelastineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Baclofen.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.Illicit
BeclamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Beclamide.Experimental
BefunololThe serum concentration of Befunolol can be increased when it is combined with Prochlorperazine.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benperidol.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzoctamine.Approved
BenzphetamineProchlorperazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzyl alcohol.Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Prochlorperazine.Approved
BezitramideThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bifeprunox.Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Prochlorperazine.Approved
BL-1020The risk or severity of adverse effects can be increased when Prochlorperazine is combined with BL-1020.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Blonanserin.Approved, Investigational
BoceprevirThe metabolism of Prochlorperazine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Prochlorperazine.Approved
BosentanThe serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromisoval.Experimental
BromocriptineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Prochlorperazine.Investigational
BufotenineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bufotenine.Experimental, Illicit
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Prochlorperazine.Experimental, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Prochlorperazine.Approved
BuprenorphineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Prochlorperazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butalbital.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prochlorperazine.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CamazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Captodiame.Approved, Investigational
CarbamazepineThe metabolism of Prochlorperazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbinoxamine.Approved
CarbromalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbromal.Experimental
CarfentanilThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Caroxazone.Withdrawn
CarteololThe serum concentration of Carteolol can be increased when it is combined with Prochlorperazine.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Prochlorperazine.Approved, Investigational
CathinoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cathinone.Illicit
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
CeritinibThe serum concentration of Prochlorperazine can be increased when it is combined with Ceritinib.Approved
CerlapirdineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlordiazepoxide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Prochlorperazine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Prochlorperazine.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorphentermineProchlorperazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorproethazine.Experimental
ChlorproguanilThe risk or severity of QTc prolongation can be increased when Chlorproguanil is combined with Prochlorperazine.Investigational
ChlorpromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorzoxazone.Approved
CilansetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cilansetron.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinolazepam.Approved
CisaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cisatracurium.Approved
CitalopramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prochlorperazine.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be increased when it is combined with Prochlorperazine.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clothiapine.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clotiazepam.Approved, Illicit
ClotrimazoleThe metabolism of Prochlorperazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CloxazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Prochlorperazine.Approved
CobicistatThe metabolism of Prochlorperazine can be decreased when combined with Cobicistat.Approved
CodeineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Codeine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Colistin.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Prochlorperazine.Approved, Investigational
CrizotinibThe metabolism of Prochlorperazine can be decreased when combined with Crizotinib.Approved
CurcuminThe metabolism of Prochlorperazine can be decreased when combined with Curcumin.Approved, Investigational
CyamemazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclizine.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prochlorperazine.Approved
Cycloguanil embonateThe risk or severity of QTc prolongation can be increased when Cycloguanil embonate is combined with Prochlorperazine.Experimental
CyclopropaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclopropane.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DanazolThe metabolism of Prochlorperazine can be decreased when combined with Danazol.Approved
DantroleneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapoxetine.Investigational
DapsoneThe risk or severity of QTc prolongation can be increased when Dapsone is combined with Prochlorperazine.Approved, Investigational
DarunavirThe metabolism of Prochlorperazine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.Approved, Investigational
DeanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Prochlorperazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeferoxamineThe risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine.Approved, Investigational
DelavirdineThe metabolism of Prochlorperazine can be decreased when combined with Delavirdine.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Prochlorperazine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Detomidine.Vet Approved
DeutetrabenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Prochlorperazine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Prochlorperazine.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dextofisopam.Investigational
DextroamphetamineProchlorperazine may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.Approved
DextromoramideThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diazepam.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diethyl ether.Experimental
DiethylpropionProchlorperazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prochlorperazine.Approved, Investigational
DihydroetorphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemThe metabolism of Prochlorperazine can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dixyrazine.Experimental
DofetilideProchlorperazine may decrease the excretion rate of Dofetilide which could result in a higher serum level.Approved, Investigational
DolasetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doramectin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Prochlorperazine.Approved
DotarizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Prochlorperazine.Approved, Investigational
DoxycyclineThe risk or severity of QTc prolongation can be increased when Doxycycline is combined with Prochlorperazine.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
DPDPEThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Illicit
DronedaroneThe metabolism of Prochlorperazine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.Approved
EcopipamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ecopipam.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Edivoxetine.Investigational
EfavirenzThe metabolism of Prochlorperazine can be decreased when combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eltanolone.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be increased when it is combined with Prochlorperazine.Experimental
EperisoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prochlorperazine.Approved
ErythromycinThe metabolism of Prochlorperazine can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololThe serum concentration of Esatenolol can be increased when it is combined with Prochlorperazine.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Esmirtazapine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Prochlorperazine.Approved
EsreboxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prochlorperazine.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethadione.Experimental
EthanolProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etifoxine.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Prochlorperazine.Withdrawn
EtorphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Prochlorperazine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ezogabine.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fexofenadine.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Prochlorperazine can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Prochlorperazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prochlorperazine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Prochlorperazine can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fospropofol.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Prochlorperazine.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Prochlorperazine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin Enacarbil.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gallamine Triethiodide.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with GENTAMICIN C1A.Experimental
GepefrineProchlorperazine may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Glutethimide.Approved, Illicit
GranisetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe risk or severity of QTc prolongation can be increased when Halofantrine is combined with Prochlorperazine.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Heptabarbital.Approved
HeroinThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hydracarbazine.Experimental
HydrocodoneProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyamphetamineProchlorperazine may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Prochlorperazine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hypericin.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Idalopirdine.Investigational
IdelalisibThe metabolism of Prochlorperazine can be decreased when combined with Idelalisib.Approved
IfenprodilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Imagabalin.Investigational
ImatinibThe metabolism of Prochlorperazine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Prochlorperazine.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indalpine.Investigational, Withdrawn
IndenololThe serum concentration of Indenolol can be increased when it is combined with Prochlorperazine.Withdrawn
IndinavirThe metabolism of Prochlorperazine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indiplon.Investigational
Iofetamine I-123Prochlorperazine may decrease the stimulatory activities of Iofetamine I-123.Approved
IprazochromeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iproniazid.Withdrawn
IsavuconazoleThe serum concentration of Prochlorperazine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Prochlorperazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Isepamicin.Experimental
IsocarboxazidThe therapeutic efficacy of Prochlorperazine can be increased when used in combination with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Prochlorperazine can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe metabolism of Prochlorperazine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Prochlorperazine can be increased when it is combined with Ivacaftor.Approved
KanamycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Prochlorperazine can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with L-Tryptophan.Approved, Nutraceutical, Withdrawn
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Prochlorperazine.Approved
LacosamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.Approved, Investigational
LandiololThe serum concentration of Landiolol can be increased when it is combined with Prochlorperazine.Investigational
LanicemineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.Approved, Investigational
LevobetaxololThe serum concentration of Levobetaxolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Prochlorperazine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Levorphanol.Approved
LincomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Prochlorperazine.Approved, Investigational
LisdexamfetamineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lithium carbonate.Approved
Lithium cationLithium cation may increase the neurotoxic activities of Prochlorperazine.Experimental
LofentanilThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Lofentanil.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of Prochlorperazine can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Prochlorperazine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loratadine.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Prochlorperazine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lormetazepam.Approved
LorpiprazoleThe serum concentration of Prochlorperazine can be increased when it is combined with Lorpiprazole.Approved
LortalamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lortalamine.Experimental
LovastatinThe metabolism of Prochlorperazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.Approved
LuliconazoleThe serum concentration of Prochlorperazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Prochlorperazine can be increased when combined with Lumacaftor.Approved
LumateperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lumateperone.Investigational
LumefantrineThe risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Prochlorperazine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with m-Chlorophenylpiperazine.Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium acetateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium aspartate.Experimental
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium glycinate.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium orotate.Experimental
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium phosphateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium phosphate.Experimental
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Prochlorperazine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prochlorperazine.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Prochlorperazine.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mebicar.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Medetomidine.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Medifoxamine.Experimental
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Prochlorperazine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melperone.Approved, Investigational
MephedroneProchlorperazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mephenoxalone.Experimental
MephentermineProchlorperazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mephenytoin.Investigational, Withdrawn
MepindololThe serum concentration of Mepindolol can be increased when it is combined with Prochlorperazine.Experimental
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.Approved, Illicit
MeptazinolThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Meptazinol.Experimental
MequitazineProchlorperazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineProchlorperazine may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methaqualone.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methohexital.Approved
MethotrimeprazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineProchlorperazine may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenobarbital.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methysergide.Approved
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Prochlorperazine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metocurine Iodide.Approved, Withdrawn
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
MetyrosineProchlorperazine may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Prochlorperazine.Approved, Investigational
MibefradilThe metabolism of Prochlorperazine can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Prochlorperazine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.Approved, Illicit
MidomafetamineProchlorperazine may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Prochlorperazine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Investigational
MirtazapineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Prochlorperazine can be decreased when it is combined with Mitotane.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mivacurium.Approved
MizoribineThe risk or severity of QTc prolongation can be increased when Mizoribine is combined with Prochlorperazine.Investigational
MK-212The risk or severity of adverse effects can be increased when Prochlorperazine is combined with MK-212.Investigational
MMDAProchlorperazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.Approved, Investigational
ModafinilThe serum concentration of Prochlorperazine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mosapramine.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when Prochlorperazine is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Prochlorperazine.Approved
NafcillinThe serum concentration of Prochlorperazine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Nalbuphine.Approved
NaloxoneThe metabolism of Prochlorperazine can be decreased when combined with Naloxone.Approved, Vet Approved
NaltrexoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Neamine.Experimental
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nefiracetam.Investigational
NelfinavirThe metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.Approved
NeocitrullamonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Netilmicin.Approved, Investigational
NetupitantThe serum concentration of Prochlorperazine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Prochlorperazine can be increased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Niaprazine.Experimental
NicardipineThe metabolism of Prochlorperazine can be decreased when combined with Nicardipine.Approved, Investigational
NicomorphineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Nicomorphine.Experimental
NilotinibThe metabolism of Prochlorperazine can be decreased when combined with Nilotinib.Approved, Investigational
NisoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrous oxide.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nordazepam.Approved
NormethadoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prochlorperazine.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Prochlorperazine.Approved, Investigational
OlaparibThe metabolism of Prochlorperazine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Opipramol.Investigational
OpiumThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Opium.Approved, Illicit
OrphenadrineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Prochlorperazine can be increased when it is combined with Osimertinib.Approved
OxaflozaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Prochlorperazine.Approved
OxycodoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pancuronium.Approved
ParaldehydeProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paramethadione.Approved
PargylineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paroxetine.Approved, Investigational
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Penfluridol.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Penimepicycline.Experimental
PentazocineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Prochlorperazine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perazine.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.Approved
PethidineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Pethidine.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenacemide.Approved
PhenazocineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Prochlorperazine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phensuximide.Approved
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Prochlorperazine.Approved, Illicit
PhenytoinThe metabolism of Prochlorperazine can be increased when combined with Phenytoin.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimozide.Approved
PinazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pinazepam.Experimental
PindololThe serum concentration of Pindolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipecuronium.Approved
PiperaquineThe risk or severity of QTc prolongation can be increased when Piperaquine is combined with Prochlorperazine.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipotiazine.Approved, Investigational
PiribedilThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pirlindole.Approved
PitolisantThe serum concentration of Prochlorperazine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivagabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Prochlorperazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Prochlorperazine.Approved
PramipexoleProchlorperazine may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Prochlorperazine can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pridinol.Experimental
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Prochlorperazine.Approved
PrimidoneThe metabolism of Prochlorperazine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prochlorperazine.Approved, Investigational
ProgabideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Progabide.Approved, Investigational
ProguanilThe risk or severity of QTc prolongation can be increased when Proguanil is combined with Prochlorperazine.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Prochlorperazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Prochlorperazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Prochlorperazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propanidid.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propiopromazine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Prochlorperazine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prochlorperazine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Proxibarbal.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Prochlorperazine is combined with PRX-08066.Investigational
PseudoephedrineProchlorperazine may decrease the stimulatory activities of Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pyrantel.Approved, Vet Approved
PyrimethamineThe risk or severity of QTc prolongation can be increased when Pyrimethamine is combined with Prochlorperazine.Approved, Investigational, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pyrithyldione.Experimental
PyronaridineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Prochlorperazine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.Approved
QuinacrineThe risk or severity of QTc prolongation can be increased when Quinacrine is combined with Prochlorperazine.Approved, Investigational
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine.Approved, Investigational
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Prochlorperazine.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Prochlorperazine.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramosetron.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remacemide.Investigational
RemifentanilThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remoxipride.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ribostamycin.Approved, Investigational
RifampicinThe metabolism of Prochlorperazine can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Prochlorperazine can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Prochlorperazine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe metabolism of Prochlorperazine can be increased when combined with Rifaximin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Riluzole.Approved, Investigational
RimexoloneThe metabolism of Prochlorperazine can be increased when combined with Rimexolone.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ritanserin.Investigational
RitobegronProchlorperazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Prochlorperazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.Approved
RocuroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Romifidine.Vet Approved
RopiniroleProchlorperazine may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineProchlorperazine may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when Prochlorperazine is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Prochlorperazine.Approved
SafinamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Prochlorperazine can be decreased when combined with Saquinavir.Approved, Investigational
SaredutantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Saredutant.Investigational
SarilumabThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Sarilumab.Approved, Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Prochlorperazine.Approved, Illicit, Investigational, Withdrawn
SiltuximabThe serum concentration of Prochlorperazine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Prochlorperazine can be increased when it is combined with Simeprevir.Approved
SisomicinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sisomicin.Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
SotalolThe serum concentration of Sotalol can be increased when it is combined with Prochlorperazine.Approved
St. John's WortThe serum concentration of Prochlorperazine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Prochlorperazine can be increased when it is combined with Stiripentol.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Succinylcholine.Approved
SufentanilThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Sufentanil.Approved, Investigational
SulfadoxineThe risk or severity of QTc prolongation can be increased when Sulfadoxine is combined with Prochlorperazine.Approved, Investigational
SulpirideProchlorperazine may increase the antipsychotic activities of Sulpiride.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.Approved, Investigational
SuvorexantProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TafenoquineThe risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Prochlorperazine.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Talbutal.Approved, Illicit
TalinololThe serum concentration of Talinolol can be increased when it is combined with Prochlorperazine.Investigational
TalopramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Talopram.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Prochlorperazine is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Tedizolid phosphate is combined with Prochlorperazine.Approved
TegaserodThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tegaserod.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Prochlorperazine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Prochlorperazine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.Approved, Investigational
TertatololThe serum concentration of Tertatolol can be increased when it is combined with Prochlorperazine.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of QTc prolongation can be increased when Tetrandrine is combined with Prochlorperazine.Experimental
TetrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrodotoxin.Investigational
ThalidomideProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Prochlorperazine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiapride.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Tilidine.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Prochlorperazine.Approved
TipranavirThe metabolism of Prochlorperazine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tobramycin.Approved, Investigational
TocilizumabThe serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.Approved
TofisopamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.Approved
TramadolThe risk or severity of hypotension and central nervous system depression can be increased when Prochlorperazine is combined with Tramadol.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prochlorperazine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trichloroethylene.Approved
TriclofosThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trimethadione.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prochlorperazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triprolidine.Approved
TroleandomycinThe metabolism of Prochlorperazine can be decreased when combined with Troleandomycin.Approved
TropisetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valnoctamide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Veralipride.Experimental
VerapamilThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Prochlorperazine.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vinyl ether.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vinylbital.Experimental
VoriconazoleThe metabolism of Prochlorperazine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Prochlorperazine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when Prochlorperazine is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Xylazine.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Prochlorperazine is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Prochlorperazine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine.Approved, Investigational
ZolpidemProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

References

Synthesis Reference
US2902484
General References
Not Available
External Links
Human Metabolome Database
HMDB0014577
KEGG Drug
D00493
KEGG Compound
C07403
PubChem Compound
4917
PubChem Substance
46509018
ChemSpider
4748
BindingDB
78434
ChEBI
8435
ChEMBL
CHEMBL728
Therapeutic Targets Database
DAP000373
PharmGKB
PA451114
HET
P77
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prochlorperazine
ATC Codes
N05AB04 — Prochlorperazine
AHFS Codes
  • 56:22.08 — Antihistamines
  • 28:16.08.24 — Phenothiazines
PDB Entries
3m0w
FDA label
Download (617 KB)
MSDS
Download (73.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMigraines1
2CompletedTreatmentNausea and Vomiting1
2TerminatedTreatmentBenign Headache1
3Active Not RecruitingTreatmentMigraine Disorders1
3CompletedSupportive CareNausea1
3CompletedSupportive CareNausea and Vomiting / Unspecified Adult Solid Tumor, Protocol Specific1
3RecruitingSupportive CareCarcinoma, Breast1
3TerminatedTreatmentHeadaches1
4CompletedTreatmentHeadaches1
4CompletedTreatmentMigraines2
4RecruitingPreventionLaparoscopic Sleeve Gastrectomy / Prophylaxis against postoperative nausea and vomiting1
4RecruitingTreatmentHeadaches1
4TerminatedTreatmentMigrainous Headache1
Not AvailableCompletedNot AvailableSchizophrenic Disorders1
Not AvailableCompletedTreatmentAcute Migraine Headache1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
  • Glaxosmithkline
  • Paddock laboratories inc
  • Able laboratories inc
  • G and w laboratories inc
  • Alpharma us pharmaceuticals division
  • Morton grove pharmaceuticals inc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Cadista pharmaceuticals inc
Packagers
  • Apotheca Inc.
  • A-S Medication Solutions LLC
  • Barr Pharmaceuticals
  • Baxter International Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • Bryant Ranch Prepack
  • Cadista Pharmaceuticals Inc.
  • Cardinal Health
  • Comprehensive Consultant Services Inc.
  • Corepharma LLC
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • G & W Labs
  • General Injectables and Vaccines Inc.
  • H.J. Harkins Co. Inc.
  • Heartland Repack Services LLC
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Kaiser Foundation Hospital
  • Liberty Pharmaceuticals
  • Medisca Inc.
  • Medvantx Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Nucare Pharmaceuticals Inc.
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Par Pharmaceuticals
  • Patient First Corp.
  • PCA LLC
  • PD-Rx Pharmaceuticals Inc.
  • Pharma Pac LLC
  • Pharmaceutical Utilization Management Program VA Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepackage Specialists
  • Prepak Systems Inc.
  • Prescript Pharmaceuticals
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Sandhills Packaging Inc.
  • Sandoz
  • Southwood Pharmaceuticals
  • Stat Rx Usa
  • Teva Pharmaceutical Industries Ltd.
  • UDL Laboratories
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
SuppositoryRectal10 mg
TabletOral10 mg
TabletOral5 mg
SuppositoryRectal25 mg/1
InjectionIntramuscular5 mg/mL
InjectionIntramuscular; Intravenous10 mg/2mL
InjectionIntramuscular; Intravenous5 mg/mL
TabletOral10 mg/1
TabletOral5 mg/61
TabletOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
LiquidIntramuscular; Intravenous5 mg
SolutionIntramuscular; Intravenous5 mg
SyrupOral5 mg
Prices
Unit descriptionCostUnit
Prochlorperazine mal powder4.77USD g
Compazine 25 mg suppository4.25USD suppository
Prochlorperazine 25 mg suppository3.13USD suppository
Compro 25 mg suppository3.05USD suppository
Compazine 5 mg tablet1.82USD tablet
Compazine 10 mg tablet1.8USD tablet
Prochlorperazine 5 mg/ml vial1.22USD ml
Prochlorperazine 5 mg/ml0.91USD ml
Prochlorperazine Maleate 10 mg tablet0.88USD tablet
Sandoz Prochlorperazine 10 mg Suppository0.87USD suppository
Prochlorperazine 10 mg tablet0.85USD tablet
Prochlorperazine Maleate 5 mg tablet0.59USD tablet
Prochlorperazine 5 mg tablet0.57USD tablet
Apo-Prochlorazine 10 mg Tablet0.21USD tablet
Apo-Prochlorazine 5 mg Tablet0.17USD tablet
Novamine 15% iv solution0.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)228 °CPhysProp
water solubility15 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.88HANSCH,C ET AL. (1995)
logS-4.4ADME Research, USCD
pKa8.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.011 mg/mLALOGPS
logP4.67ALOGPS
logP4.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity109.81 m3·mol-1ChemAxon
Polarizability41.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9781
Caco-2 permeable+0.7729
P-glycoprotein substrateSubstrate0.8537
P-glycoprotein inhibitor IInhibitor0.817
P-glycoprotein inhibitor IIInhibitor0.8577
Renal organic cation transporterInhibitor0.7615
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateNon-substrate0.5179
CYP450 3A4 substrateNon-substrate0.5346
CYP450 1A2 substrateInhibitor0.9376
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.9723
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.7676
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.8999
CarcinogenicityNon-carcinogens0.9456
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3496 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8165
hERG inhibition (predictor II)Inhibitor0.786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (10.4 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-01vo-9853000000-ba88fedd94e150c34e1a
GC-MS Spectrum - EI-BGC-MSsplash10-0229-7933000000-4e14a9a9728c361941d3
Mass Spectrum (Electron Ionization)MSsplash10-022c-9752000000-533ac31876b44d82f2aa
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-00fr-0219000000-abf2f9a1f6a1efb497b8

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Phenothiazines
Direct Parent
Phenothiazines
Alternative Parents
Alkyldiarylamines / Diarylthioethers / N-methylpiperazines / Benzenoids / Aryl chlorides / 1,4-thiazines / Trialkylamines / Azacyclic compounds / Organopnictogen compounds / Organochlorides
show 1 more
Substituents
Phenothiazine / Alkyldiarylamine / Diarylthioether / Aryl thioether / Tertiary aliphatic/aromatic amine / N-alkylpiperazine / N-methylpiperazine / Para-thiazine / Aryl chloride / Aryl halide
show 15 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenothiazines, organochlorine compound, N-alkylpiperazine, N-methylpiperazine (CHEBI:8435)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Roberge RJ: Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch. J Emerg Med. 2006 Apr;30(3):299-302. [PubMed:16677982]
  3. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092]
  4. Vinson DR: Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine. J Emerg Med. 2006 Aug;31(2):139-45. [PubMed:17044574]
  5. Callan JE, Kostic MA, Bachrach EA, Rieg TS: Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5. [PubMed:18534808]
  6. Narita M, Takei D, Shiokawa M, Tsurukawa Y, Matsushima Y, Nakamura A, Takagi S, Asato M, Ikegami D, Narita M, Amano T, Niikura K, Hashimoto K, Kuzumaki N, Suzuki T: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol. 2008 Dec 14;600(1-3):105-9. doi: 10.1016/j.ejphar.2008.10.030. Epub 2008 Oct 21. [PubMed:18955042]
  7. Golembiewski J, Tokumaru S: Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006 Dec;21(6):385-97. [PubMed:17169748]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:40